PURPOSE: Limited tools exist to predict the risk of chemotherapy toxicity in older adults with early-stage breast cancer. METHODS: Patients of age ≥ 65 years with stage I-III breast cancer from 16 institutions treated with neoadjuvant or adjuvant chemotherapy were prospectively evaluated for geriatric and clinical features predictive of grade 3-5 chemotherapy toxicity. Logistic regression with best-subsets selection was used to identify and incorporate independent predictors of toxicity into a model with weighted variable scoring. Model performance was evaluated using area under the ROC curve (AUC) and goodness-of-fit statistics. The model was internally and externally validated. RESULTS: In 473 patients (283 in development and 190 in validation cohort), 46% developed grade 3-5 chemotherapy toxicities. Eight independent predictors were identified (each assigned weighted points): anthracycline use (1 point), stage II or III (3 points), planned treatment duration > 3 months (4 points), abnormal liver function (3 points), low hemoglobin (3 points), falls (4 points), limited walking (3 points), and lack of social support (3 points). We calculated risk scores for each patient and defined three risk groups: low (0-5 points), intermediate (6-11 points), or high (≥ 12 points). In the development cohort, the rates of grade 3-5 chemotherapy toxicity for these three groups were 19%, 54%, and 87%, respectively (P < .01). In the validation cohort, the corresponding toxicity rates were 27%, 45%, and 76%. The AUC was 0.75 (95% CI, 0.70 to 0.81) in the development cohort and 0.69 (95% CI, 0.62 to 0.77) in the validation cohort. Risk groups were also associated with hospitalizations and reduced dose intensity (P < .01). CONCLUSION: The Cancer and Aging Research Group-Breast Cancer (CARG-BC) score was developed and validated to predict grade 3-5 chemotherapy toxicity in older adults with early-stage breast cancer.
PURPOSE: Limited tools exist to predict the risk of chemotherapy toxicity in older adults with early-stage breast cancer. METHODS: Patients of age ≥ 65 years with stage I-III breast cancer from 16 institutions treated with neoadjuvant or adjuvant chemotherapy were prospectively evaluated for geriatric and clinical features predictive of grade 3-5 chemotherapy toxicity. Logistic regression with best-subsets selection was used to identify and incorporate independent predictors of toxicity into a model with weighted variable scoring. Model performance was evaluated using area under the ROC curve (AUC) and goodness-of-fit statistics. The model was internally and externally validated. RESULTS: In 473 patients (283 in development and 190 in validation cohort), 46% developed grade 3-5 chemotherapy toxicities. Eight independent predictors were identified (each assigned weighted points): anthracycline use (1 point), stage II or III (3 points), planned treatment duration > 3 months (4 points), abnormal liver function (3 points), low hemoglobin (3 points), falls (4 points), limited walking (3 points), and lack of social support (3 points). We calculated risk scores for each patient and defined three risk groups: low (0-5 points), intermediate (6-11 points), or high (≥ 12 points). In the development cohort, the rates of grade 3-5 chemotherapy toxicity for these three groups were 19%, 54%, and 87%, respectively (P < .01). In the validation cohort, the corresponding toxicity rates were 27%, 45%, and 76%. The AUC was 0.75 (95% CI, 0.70 to 0.81) in the development cohort and 0.69 (95% CI, 0.62 to 0.77) in the validation cohort. Risk groups were also associated with hospitalizations and reduced dose intensity (P < .01). CONCLUSION: The Cancer and Aging Research Group-Breast Cancer (CARG-BC) score was developed and validated to predict grade 3-5 chemotherapy toxicity in older adults with early-stage breast cancer.
Authors: Martine Extermann; Ivette Boler; Richard R Reich; Gary H Lyman; Richard H Brown; Joseph DeFelice; Richard M Levine; Eric T Lubiner; Pablo Reyes; Frederic J Schreiber; Lodovico Balducci Journal: Cancer Date: 2011-11-09 Impact factor: 6.860
Authors: Arti Hurria; Supriya Gupta; Marjorie Zauderer; Enid L Zuckerman; Harvey J Cohen; Hyman Muss; Miriam Rodin; Katherine S Panageas; Jimmie C Holland; Leonard Saltz; Mark G Kris; Ariela Noy; Jorge Gomez; Ann Jakubowski; Clifford Hudis; Alice B Kornblith Journal: Cancer Date: 2005-11-01 Impact factor: 6.860
Authors: Candyce H Kroenke; Laura D Kubzansky; Eva S Schernhammer; Michelle D Holmes; Ichiro Kawachi Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: Erin B Moth; Belinda E Kiely; Natalie Stefanic; Vasikaran Naganathan; Andrew Martin; Peter Grimison; Martin R Stockler; Philip Beale; Prunella Blinman Journal: J Geriatr Oncol Date: 2018-09-14 Impact factor: 3.599
Authors: Darryl Outlaw; Maya Abdallah; Luiz A Gil-Jr; Smith Giri; Tina Hsu; Jessica L Krok-Schoen; Gabor Liposits; Tânia Madureira; Joana Marinho; Ishwaria M Subbiah; Gina Tuch; Grant R Williams Journal: Semin Radiat Oncol Date: 2022-04 Impact factor: 5.934
Authors: Lauren Brown; Samer A Naffouje; Christine Sam; Christine Laronga; M Catherine Lee Journal: Breast Cancer Res Treat Date: 2022-10-08 Impact factor: 4.624
Authors: Daneng Li; Can-Lan Sun; Rebecca Allen; Christiana J Crook; Abrahm Levi; Richard Ballena; Heidi D Klepin; Rawad Elias; Supriya G Mohile; William P Tew; Cynthia Owusu; Hyman B Muss; Stuart M Lichtman; Cary P Gross; Andrew E Chapman; Ajeet Gajra; Harvey J Cohen; Vani Katheria; Arti Hurria; William Dale Journal: Oncologist Date: 2022-02-03
Authors: Annelieke A Lemij; Nienke A de Glas; Marloes G M Derks; Esther Bastiaannet; Jos W S Merkus; Titia E Lans; Carmen C van der Pol; Thijs van Dalen; Annelie J E Vulink; Leander van Gerven; Onno R Guicherit; Eugenie M H Linthorst-Niers; Frederiek van den Bos; Judith R Kroep; Gerrit Jan Liefers; Johanneke E A Portielje Journal: Breast Cancer Res Treat Date: 2022-04-19 Impact factor: 4.624
Authors: Marie A Flannery; Eva Culakova; Beverly E Canin; Luke Peppone; Erika Ramsdale; Supriya G Mohile Journal: J Clin Oncol Date: 2021-05-27 Impact factor: 44.544
Authors: Neil Carleton; Azadeh Nasrazadani; Kristine Gade; Sushil Beriwal; Parul N Barry; Adam M Brufsky; Rohit Bhargava; Wendie A Berg; Margarita L Zuley; G J van Londen; Oscar C Marroquin; Darcy L Thull; Phuong L Mai; Emilia J Diego; Michael T Lotze; Steffi Oesterreich; Priscilla F McAuliffe; Adrian V Lee Journal: Lancet Healthy Longev Date: 2022-01-05